Effects of acotiamide on esophageal motility in healthy subjects: a randomized, double-blind, placebo-controlled crossover study
Effects of acotiamide on esophageal motility in healthy subjects: a randomized, double-blind, placebo-controlled crossover study
复制标题
阿考酰胺对健康受试者食管运动的影响：一项随机、双盲、安慰剂对照交叉研究
DOI：
10.1007/s10388-016-0559-z
复制
发表时间：
2017
期刊：
影响因子：
2.4
通讯作者：
Iwakiri K
中科院分区：
文献类型：
--
作者：
Hoshino S;Takenouchi N;Hanada Y;Umezawa M;Sano H;Kawami K;Hoshikawa Y;Kawagoe T;Nomura T;Hoshihara Y;Iwakiri K
acotiamide是一种通过促进乙酰胆碱释放而具有促动力学活性的新药。然而，其对食管运动的影响目前尚不清楚。因此，我们在此研究了阿哥替胺对健康无症状受试者食管运动的影响。方法30名健康受试者在随机、双盲、安慰剂对照的交叉研究中，每天3次接受100 mg的阿哥替胺或安慰剂治疗，连续7天，间隔28天洗脱期。在治疗第7天，使用高分辨率测压仪评估食管胃交界压力、综合松弛压力和初级蠕动。结果阿可丁胺组食管胃结压力（中位28.2 mmHg）明显高于安慰剂组（24.0 mmHg），而两组之间的整体松弛压力、远端收缩积分或收缩模式无显著差异。在13名有蠕动异常的健康受试者中，阿可替胺组和安慰剂组在综合松弛压力和远端收缩积分方面无显著差异；但阿可替胺组食管胃交界压力（阿可替胺23.4 mmHg；安慰剂21.7 mmHg）明显升高，收缩模式明显改善，食管蠕动异常发生率明显降低。结论阿可替胺可改善蠕动异常患者的蠕动模式，减少微弱的蠕动，并伴有小的断裂。
BackgroundAcotiamide is a new drug that exhibits prokinetic activity by enhancing the release of acetylcholine. However, its effects on esophageal motility currently remain unknown. Therefore, we herein investigated the effects of acotiamide on esophageal motility in healthy, asymptomatic subjects.MethodsThirty healthy subjects received 100 mg of acotiamide or placebo three times a day for 7 days separated by a 28-day washout period in a randomized, double-blind, placebo-controlled crossover study. On the seventh day of treatment, esophagogastric junction pressure, integrated relaxation pressure, and primary peristalsis were assessed using high-resolution manometry.ResultsEsophagogastric junction pressure was significantly higher in the acotiamide group (median 28.2 mmHg) than in the placebo group (24.0 mmHg), whereas no significant differences were observed in integrated relaxation pressure, the distal contractile integral, or contraction patterns between the two groups. Among 13 healthy subjects with peristaltic abnormalities, no significant differences were noted in integrated relaxation pressure or the distal contractile integral between the acotiamide and placebo groups; however, the esophagogastric junction pressure (acotiamide 23.4 mmHg; placebo 21.7 mmHg) significantly increased, the contraction pattern significantly improved, and the frequency of esophageal peristaltic abnormalities significantly decreased in the acotiamide group.ConclusionAcotiamide improves the peristaltic pattern in patients with peristaltic abnormalities by decreasing weak peristalsis with a small break.